Hospital chiefs and trustees defend this as boosting public-private partnerships, but critics say these board positions — some paying millions of dollars — raise troubling issues of conflict of interest and hospital priorities. More
The Surgeon General nominee will only treat corporate America's woes More
Pharma companies have inked a series of federal settlements over payments to charity organizations, which the federal government argues are a “conduit” to boosting drug sales. Now, after an opioid investigation, two Senators want all those charity payments disclosed publicly. More
Pharmaceutical interaction in US residencies is common. This study explores the extent and type of learner interactions in US family medicine residencies with the pharmaceutical industry and compares interactions from 2008, 2013, and 2019. More
New research confirms what drug companies have long known: Industry cash and gifts influence how doctors prescribe drugs for their patients. More
A Trump administration maneuver allows executives who are leading the federal effort to keep investments in drug companies that would benefit from the pandemic response. More
A federal watchdog agency has issued an unusual warning to the drug industry to avoid using speaker programs to boost prescriptions. More
In 2017, 12 of the 19 largest pharmaceutical and biotech companies in the world reportedly had at least 1 member of the board of directors who also served a leadership role at a nonprofit AMC. More
The administration calls Moncef Slaoui, who leads its vaccine race, a “contractor” to sidestep rules against personally profiting from government positions. Slaoui owns $10 million in stock of a company working with his team to develop a vaccine. More
Industry payments can encourage the uptake of new medicines and devices in some of the most influential medical institutions in the country. More